Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $1.34 is 91.43% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 1.3928||$ 4.7895|
|Low:||$ 1.32||$ 0.70|
Company Description (as filed with the SEC)
We are a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. As described below, we, through our subsidiary Aegerion, develop and commercialize two rare disease products, metreleptin and lomitapide. During the year ended December 31, 2018, net revenues from metreleptin and lomitapide were $130.4 million, of which $83.4 million was derived from prescriptions for metreleptin and lomitapide written in the U.S., and $47.0 million was derived from prescriptions written for and royalties on sales of metreleptin and lomitapide outside the U.S. As of December 31, 2018, we had approximately $45.2 million in cash and cash equivalents, of which $31.9 million was held and controlled by our subsidiary Aegerion. ... More ...
Nasdaq Official Price
Apr. 18, 2019
Apr. 18, 2019